Celecoxib for ENT Pain Management

Surgeons have a unique opportunity to reduce opioid prescriptions - and therefore potential opioid dependence, morbidity and mortality - by altering prescribing patterns in the perioperative period. This study aims to determine if celecoxib is a viable alternative for acute pain control in the postoperative setting for head and neck surgeries which could significantly reduce the amount of narcotic pain pills in circulation and can be extrapolated to other otolaryngologic procedures.

Inclusion criteria

• Ability to understand and the willingness to sign a written informed consent document
• Willing to comply with all study procedures and be available for the duration of the study
• Ability to take oral medication
• Undergoing superficial parotidectomy
• Individuals at least 18 years of age
• Adequate organ function as indicated by standard laboratory tests: hematology (complete blood count), clinical chemistry

Exclusion criteria

• History of NSAIDs contraindication (severe congestive heart failure, CABG within 14 days, arrhythmias, significant coronary artery disease, cardiomyopathy, severe hepatic impairment, history of peptic ulcer disease or GI bleeding, use of anticoagulation (other than prophylactic aspirin)
• History of uncontrolled hypertension, cerebrovascular accident, sulfa allergy, allergy to celecoxib
• Concurrent use of CYP2C9 potentiator/inhibitor
• Use of investigational drugs, biologics, or devices within 30 days prior to randomization.
• Individuals who are pregnant, lactating or planning on becoming pregnant during the study.
• Not suitable for study participation due to other reasons at the discretion of the investigators.